GB201021390D0 - Treatment of obesity or diabetes with bile acid sequestrants - Google Patents

Treatment of obesity or diabetes with bile acid sequestrants

Info

Publication number
GB201021390D0
GB201021390D0 GBGB1021390.8A GB201021390A GB201021390D0 GB 201021390 D0 GB201021390 D0 GB 201021390D0 GB 201021390 A GB201021390 A GB 201021390A GB 201021390 D0 GB201021390 D0 GB 201021390D0
Authority
GB
United Kingdom
Prior art keywords
obesity
diabetes
treatment
bile acid
acid sequestrants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1021390.8A
Other versions
GB2476384A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Satiogen Pharmaceuticals Inc
Original Assignee
Satiogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satiogen Pharmaceuticals Inc filed Critical Satiogen Pharmaceuticals Inc
Publication of GB201021390D0 publication Critical patent/GB201021390D0/en
Publication of GB2476384A publication Critical patent/GB2476384A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
GB1021390A 2009-12-18 2010-12-16 Labile bile acid sequestrant for use in the treatment of obesity or diabetes Withdrawn GB2476384A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28813409P 2009-12-18 2009-12-18

Publications (2)

Publication Number Publication Date
GB201021390D0 true GB201021390D0 (en) 2011-01-26
GB2476384A GB2476384A (en) 2011-06-22

Family

ID=43567346

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1021390A Withdrawn GB2476384A (en) 2009-12-18 2010-12-16 Labile bile acid sequestrant for use in the treatment of obesity or diabetes

Country Status (3)

Country Link
US (1) US20110152204A1 (en)
GB (1) GB2476384A (en)
WO (1) WO2011075539A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3023102T (en) 2010-11-08 2018-09-25 Albireo Ab Ibat inhibitors for the treatment of liver diseases
EP3498271A1 (en) * 2011-05-02 2019-06-19 Biokier, Inc. Composition and method for treatment of diabetes
EA201891154A1 (en) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи INHIBITORS OF BILIC ACID RECYCLING IN THE TREATMENT OF CHOLESTATIC DISEASES OF THE LIVER IN CHILDREN
SG10201903512SA (en) * 2011-10-28 2019-05-30 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
CN106573066A (en) 2014-06-13 2017-04-19 联合治疗学有限公司 Treprostinil formulations
CN106659726A (en) 2014-06-25 2017-05-10 Ea制药株式会社 Solid preparation, and method for preventing or reducing discoloration thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CZ201740A3 (en) * 2017-01-26 2018-08-08 Vidia spol. s r.o. Use of a preparation for peroral administration containing lignin
JP2020530448A (en) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ Cholestyramine granules, oral cholestyramine preparations, and their use
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
SG11202012151XA (en) 2018-06-20 2021-01-28 Albireo Ab Crystal modifications of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
JP2023504643A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
BR112022010505A2 (en) 2019-12-04 2022-09-06 Albireo Ab BENZOTHYA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID MODULATION
JP2023504644A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (en) 2019-12-04 2024-04-09 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
JP2023537285A (en) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
CN111956627B (en) * 2020-09-25 2022-02-18 郑州大学 Preparation method and application of drug compound with nano targeting effect for improving II type diabetes pancreatic microenvironment
KR20230106651A (en) 2020-11-12 2023-07-13 알비레오 에이비 Odevixivat for the treatment of progressive familial intrahepatic cholestasis (PFIC)
JP2024500309A (en) 2020-12-04 2024-01-09 アルビレオ エービー Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245890B (en) * 1991-04-12 1994-10-25 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS FOR ORAL USE GASTRORESANTS CONTAINING BILE ACIDS.
US5900233A (en) * 1997-10-16 1999-05-04 Day; Charles E. Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
ME00671B (en) * 2000-07-28 2011-12-20 Hoffmann La Roche New pharmaceutical composition
ES2287250T3 (en) * 2001-01-26 2007-12-16 Schering Corporation COMBINATIONS OF SEQUENCER (S) OF BILIARY ACIDS AND INHIBITOR (S) OF THE ABSORPTION OF STEROLS AND TREATMENTS FOR VASCULAR INDICATIONS.
EP1485105A1 (en) * 2002-03-18 2004-12-15 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
AU2003233653B2 (en) * 2002-05-23 2008-08-07 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
US20060024390A1 (en) * 2004-07-27 2006-02-02 Alex Schauss Palm fiber-based dietary supplements
AU2004325203A1 (en) * 2004-11-24 2006-06-01 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
US8318663B2 (en) * 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent

Also Published As

Publication number Publication date
WO2011075539A2 (en) 2011-06-23
US20110152204A1 (en) 2011-06-23
GB2476384A (en) 2011-06-22
WO2011075539A3 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
GB201021390D0 (en) Treatment of obesity or diabetes with bile acid sequestrants
GB2465879B (en) Bile acid recylcing inhibitors for treatment of obesity and diabetes
EP2575821A4 (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
IL259475A (en) Combination therapy for the treatment of diabetes
PL2405869T3 (en) Obesity treatment
GB2472496B (en) Treatment of titanium ores
EP2405869A4 (en) Obesity treatment
GB0915515D0 (en) Treatment of vasculoproliferative conditions
PT2376077T (en) Composition and method for treatment of diabetes
HK1169993A1 (en) Hsl inhibitors useful in the treatment of diabetes hsl
IL223289A0 (en) Treatment of type 2 diabetes
EP2480246A4 (en) Composition and method for treatment of diabetes
EP2389171A4 (en) Use of pterosin compounds for treating diabetes and obesity
PL2397151T3 (en) Treatment of vascular complications of diabetes
GB0908101D0 (en) Treatment of stress
EP2437771A4 (en) Compositions and methods modulating mg29 for the treatment of diabetes
EP2498794A4 (en) Method of treatment of type 2 diabetes
GB0802903D0 (en) Treatment of diabetes
GB0902157D0 (en) Treatment of obesity
GB0813310D0 (en) Treatment of obesity
ZA200907778B (en) Method of treating diabetes
GB0910904D0 (en) Treatment of diabetes and metabolic syndrome
GB0912906D0 (en) Treatment of diabetes and metabolic syndrome
GB0904271D0 (en) Treatment of diabetes and metabolic syndrome
AU2008901947A0 (en) Treatment of Ores

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)